Role of Oral Pre-exposure Prophylaxis (PrEP) in Current and Future HIV Prevention Strategies

Current HIV/AIDS Reports

Volumn 11, Issue 4, 2014, Pages 393-403

  Burns, David N ^a   Grossman, Cynthia ^b   Turpin, Jim ^a   Elharrar, Vanessa ^a   Veronese, Fulvia ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

ARVs antiretrovirals; HIV human immunodeficiency virus; PrEP pre exposure prophylaxis; Prevention

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; DRUG COMBINATION; ORGANOPHOSPHORUS COMPOUND;

ANAL INTERCOURSE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AWARENESS; COST EFFECTIVENESS ANALYSIS; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HETEROSEXUALITY; HIGH RISK BEHAVIOR; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MEDICATION COMPLIANCE; MEN WHO HAVE SEX WITH MEN; MOTIVATIONAL INTERVIEWING; PATIENT COUNSELING; PRACTICE GUIDELINE; PREEXPOSURE PROPHYLAXIS; PRESCRIPTION; PROPHYLAXIS; PROSTITUTION; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SOCIAL DESIRABILITY; WORLD HEALTH ORGANIZATION; ANALOGS AND DERIVATIVES; DRUG COMBINATION; ECONOMICS; FEMALE; HIV INFECTIONS; MALE; ORAL DRUG ADMINISTRATION; PRE-EXPOSURE PROPHYLAXIS; TRENDS;

ADMINISTRATION, ORAL; ANTI-RETROVIRAL AGENTS; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; ORGANOPHOSPHORUS COMPOUNDS; PRE-EXPOSURE PROPHYLAXIS;

EID: 84919476744     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0234-8     Document Type: Review

References (81)

1. Attia S, Egger M, Műller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397–404.
2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
3. Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245.
4. Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, et al. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014;9:e84511.
5. Boily MC, Masse B, Alsallaq R, Padian NS, Eaton JW, Vesga JF, et al. HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med. 2012;9:e1001250.
6. Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials. 2014;15:57. doi:10.1186/1745-6215-15-57.
7. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99. A large phase 3 clinical trial performed at multiple sites in North and South America, Africa, and Asia.
8. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410. A large phase 3 clinical trial performed at multiple sites in southern and east Africa. Adherence is believed to have been the highest of any of the oral PrEP clinical trials.
9. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34. Retention rates make the results of this randomized clinical trial more difficult to interpret and signal an important potential challenge for oral PrEP programs.
10. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90. A large phase 3 clinical trial performed in a population with multiple potential routes of exposure to HIV.
11. Garnett GP, Becker S, Bertozzi S. Treatment as prevention: translating efficacy trial results to population effectiveness. Curr Opin HIV AIDS. 2012;7:157–63.
12. Kretzschmar ME, van der Loeff MFS, Birrell PJ, De Angelis D, Coutinho RA. Prospects of elimination of HIV with test-and-treat strategy. Proc Natl Acad Sci U S A. 2013;110:15538–43.
13. Burns DN, DeGruttola V, Pilcher CD, Kretzschmar M, Gordon CM, Flanagan EH, et al. Toward an endgame: finding and engaging people unaware of their HIV-1 infection in treatment and prevention. AIDS Res Hum Retrovir. 2014;30:217–24.
14. Brown AE, Nardone A, Delpech VC. WHO ‘treatment as prevention’ guidelines are unlikely to decrease HIV transmission in the UK unless undiagnosed HIV infections are reduced. AIDS. 2014;28:281–3.
15. Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, Prins M, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS. 2008;22:1071–7.
16. Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, Rodger A, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One. 2013;8:e55312.
17. United States Food and Drug Administration. Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus. 2012. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ucm312264.htm
18. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22. A phase 3 clinical trial performed at multiple sites in Africa. Poor adherence prevented the investigators from addressing their primary objective.
19. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Conference on Retroviruses and Opportunistic Infections (CROI); Atlanta, GA. 2013; [Abstract 26LB]. A large phase 2B clinical trial performed at multiple sites in Africa. Poor adherence prevented the investigators from addressing their primary objectives but highlighted the critical nature of this factor to PrEP efficacy.
20. Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66:324–31.
21. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125. The authors provide an estimate of the drug concentrations required to protect MSM from HIV acquisition and relate it to adherence levels.
22. Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28:851–9.
23. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Gvetadze RJ, et al. Renal function of participants in the Bangkok Tenofovir Study—Thailand, 2005-2012. Clin Infect Dis. 2014;59:716–24. doi:10.1093/cid/ciu355.
24. Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6:e23688.
25. Mulligan K, Glidden D, Gonzales P, Ramirez-Cardich ME, Liu A, Namwongprom S, et al. Effects of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the global iPrEX study. Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA. 2011; [Abstract 94LB].
26. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65–8.
27. Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 2012;61:586–9.
28. World Health Organization. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: Recommendations for use in the context of demonstration projects. Geneva, World Health Organization. 2012. http://apps.who.int/iris/bitstream/10665/75188/1/9789241503884_eng.pdf
29. US Public Health Service. Pre-exposure prophylaxis for the prevention of HIV infection the United States—2014: a clinical practice guideline. http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf. Comprehensive clinical practice guidelines for oral PrEP in the US.
30. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva, World Health Organization. 2014. http://www.who.int/hiv/pub/guidelines/keypopulations/en/
31. Kirby T, Thornber-Dunwell M. Uptake of PrEP for HIV slow among MSM. Lancet. 2014;383:399–400.
32. Bush S, Rawlings MK, Ng LJ, Mera R. Regional differences in the utilization of Truvada for pre-exposure prophylaxis (PrEP) in the US. International conference on HIV treatment and prevention adherence; Miami, FL. 2014; [Abstract 353].
33. Holt M, Murphy DA, Callander D, Ellard J, Rosengarten M, Kippax SC, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect. 2012;88:258–63.
34. Kain T, Fowler S, Grennan T, Hart T, Maxwell J, Wilton J, et al. Low perceptions of HIV risk among Toronto MSM seeking anonymous HIV testing: objective and subjective assessments of PrEP eligibility. Controlling the HIV Epidemic with antiretrovirals conference; London, England. 2013; [Abstract 22].
35. Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60:421–7.
36. Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58:704–12. The authors provide an important snapshot of the viewpoints of infection disease physicians in the US and Canada at an early stage of oral PrEP adoption.
37. Sachdev DD, Stojanovski K, Liu AY, Buchbinder SP, Macalino GE. Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs. Clin Infect Dis. 2014;58:1786–7. The authors provide a complementary snapshot of the viewpoints of physicians practicing in the 13 metropolitan areas in the US with the highest prevalence of HIV infection.
38. Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies. Am J Prev Med. 2013;44(1 Suppl 2):S91–8.
39. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10(9):e1001511. An important first step in assessing an intervention to enhance adherence to oral PrEP.
40. Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retrovir. 2013;29:384–90.
41. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014;9:e83736.
42. Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One. 2013;8:e81997.
43. Mugwanya KK, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13:1021–8.
44. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Risk behaviors and risk factors for HIV infection among participants in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial among people who inject drugs. PLoS One. 2014;9:e92809.
45. van Sighem A, Jansen I, Bezemer D, de Wolf F, Prins M, Stolte I, et al. Increasing sexual risk behaviour among Dutch men who have sex with men: mathematical models versus prospective cohort data. AIDS. 2012;26:1840–3.
46. Birrell PJ, Gill ON, Delpech VC, Brown AE, Desai S, Chadborn TR, et al. HIV incidence in men who have sex with men in England and Wales 2001–2010: a nationwide population study. Lancet Infect Dis. 2013;13:313–8.
47. Baeten JM, Grant R. Use of antiretrovirals for HIV prevention: what do we know and what don’t we know? Curr HIV/AIDS Rep. 2013;10:142–51.
48. Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014. doi:10.1093/infdis/jiu233.
49. Dimitrov D, Boily MC, Brown ER, Hallett TB. Analytic review of modeling studies of ARV based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness. PLoS One. 2013;8:e80927.
50. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS One. 2011;6:e18165.
51. Supervie V, García-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. PNAS. 2010;107:12381–6.
52. van de Vijver DA, Nichols BE, Abbas UL, Boucher CA, Cambiano V, Eaton JW, et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS. 2013;27:2943–51.
53. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Table 16, K-22. Department of Health and Human Services. 2014. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
54. Congressional Budget Office. Prices for brand-name drugs under selected Federal programs. Congressional Budget Office. 2005. http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/64xx/doc6481/06-16-prescriptdrug.pdf
55. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the U.S.: HIV infections prevented and cost-effectiveness. AIDS. 2008;22:1829–39.
56. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48:806–15.
57. Koppenhaver RT, Sorensen SW, Farnham PG, Sansom SL. The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr. 2011;58:e51–2.
58. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the U.S. in men who have sex with men. Ann Intern Med. 2012;156:541–50.
59. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012;54:1504–13.
60. Romano J, Kashuba A, Becker S, Cummins J, Turpin J, Veronese F. Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention. AIDS Res Hum Retrovir. 2013;29:1418–27. A worthwhile summary of the current status and ongoing research into the pharmacokinetics and pharmacodynamics of potential PrEP agents.
61. Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(S1):S55–60. A helpful overview of PrEP adherence research.
62. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867–75.
63. Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, et al. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis. 2014;210:363–73.
64. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014. doi:10.1016/S1473-3099(14)70847-3. Important findings regarding the use of PrEP by MSM when they and their providers are well-informed regarding the safety and efficacy of PrEP and the agent and associated care are provided without cost. An essential caveat is that the men had all participated in previous PrEP studies.
65. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112–4.
66. Trezza CR, Kashuba ADM. Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin Pharmacokinet. 2014;53:611–24.
67. Gunawardana M, Mullen M, Moss JA, Pyles RB, Nusbaum RJ, Patel J, et al. Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One. 2013;8:e77340.
68. Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, et al. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: implications for drug disposition in HIV prevention. J Clin Pharmacol. 2014;54:574–83.
69. Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, et al. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1 % gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retrovir. 2012;28:1412–21.
70. Dezzutti CS, Uranker K, Bunge KE, Richardson-Harman N, Macio I, Hillier SL. HIV-1 infection of female genital tract tissue for use in prevention studies. J Acquir Immune Defic Syndr. 2013;63:548–54.
71. Friend DR, Kiser PF. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res. 2013;99:391–400.
72. Cottrell ML, Kashuba AD. Topical microbicides and HIV prevention in the female genital tract. J Clin Pharmacol. 2014;54:603–15.
73. Akil A, Parniak MA, Dezzutti CS, Moncla BJ, Cost MR, Li M, et al. Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv Transl Res. 2011;1:209–22.
74. Kiser PF, Johnson TJ, Clark JT. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 2012;14:62–77.
75. Dolgin E. Long-acting HIV, drugs advanced to overcome adherence challenge. Nat Med. 2014;20:323–4.
76. Kim SS, Peer D, Kumar P, Subramanya S, Wu H, Asthana D, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther. 2010;18:370–6.
77. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014;6:243–88.
78. Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med. 2014;20:296–300.
79. Kaufman MR, Cornish F, Zimmerman RS, Johnson BT. Health behavior change models for HIV prevention and AIDS care: practical recommendations for a multi-level approach. J Acquir Immune Defic Syndr. 2014;15(66 Suppl 3):S250–8.
80. Genberg BL, Lee Y, Rogers WH, Willey C, Wilson IB. Stages of change for adherence to antiretroviral medications. AIDS Patient Care STDS. 2013;27:567–72.
81. Laws MB, Lee Y, Rogers WH, Beach MC, Saha S, Korthuis PT, et al. Provider-patient communication about adherence to anti-retroviral regimens differs by patient race and ethnicity. AIDS Behav. 2014;18:1279–87.